Resistance to Immunotoxins in Cancer Therapy

Rama Shanker Verma, Ph.D., is Professor, Department of Biotechnology, the Indian Institute of Technology. Professor Verma specializes in the development of novel immunotoxins for cancer therapies. He has published 76 scientific articles, five book chapters, and several conference abstracts. He is an Elected Fellow, the Association of Microbiologists of India an Elected Fellow, the Society for Applied Biotechnology. He received the award for Excellence in Medical Biotechnology from the Society for Applied Biotechnology.

1 Targeted Cancer Therapy: History and Development of Immunotoxins.-2 Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective.-3 Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins.-4 Cell Signaling and Resistance to Immunotoxins.-5 Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms.-6 Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins .-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy .-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins.-9 Therapeutic Impact of Immune Responses in Cancer.